May 2 |
Arvinas to Present at Upcoming Investor Conferences
|
May 1 |
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
|
Apr 30 |
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
|
Apr 26 |
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
Apr 24 |
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
|
Apr 12 |
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
|
Apr 11 |
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
|
Apr 11 |
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
|
Apr 11 |
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
|
Apr 11 |
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTACĀ® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
|